Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Return on Sales (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Return on Sales for 9 consecutive years, with 21.88% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 1157.0% to 21.88% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.13% through Dec 2025, up 17.0% year-over-year, with the annual reading at 0.0% for FY2025, 4.0% up from the prior year.
  • Return on Sales hit 21.88% in Q4 2025 for Sutro Biopharma, up from 5.87% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 21.88% in Q4 2025 to a low of 11.46% in Q1 2025.
  • Historically, Return on Sales has averaged 1.48% across 5 years, with a median of 3.25% in 2021.
  • Biggest YoY gain for Return on Sales was 1157bps in 2025; the steepest drop was -699bps in 2025.
  • Year by year, Return on Sales stood at 3.58% in 2021, then decreased by -12bps to 4.01% in 2022, then skyrocketed by 107bps to 0.27% in 2023, then soared by 3675bps to 10.31% in 2024, then surged by 112bps to 21.88% in 2025.
  • Business Quant data shows Return on Sales for STRO at 21.88% in Q4 2025, 5.87% in Q3 2025, and 0.18% in Q2 2025.